David R. Fernandez, MD

Rheumatology

David R. Fernandez, MD
Rheumatology

David R. Fernandez, MD

Office Locations

Hospital for Special Surgery
525 East 71st Street
Belaire Building - 7th floor
New York, NY, 10021

Tel: 212.774.7016
Fax: 646.797.8352

Hospital for Special Surgery
525 East 71st Street
Belaire Building - 7th floor
New York, NY, 10021

Tel: 212.774.7016
Fax: 646.797.8352

Back in the Game Patient Stories

Appointments

Assistant Attending Physician, Hospital for Special Surgery

Specialty

Special Expertise

Dermatomyositis
Polymyositis Inclusion
Body Myositis
Systemic Lupus Erythematosus

Awards

Lupus and Antiphospholipid Syndrome Center of Excellence Research Fund Award, 2016
F31 Predoctoral Fellowship, NIAMS, 2008-201

Insurances Accepted

Aetna
Blue Cross HMO POS
Blue Cross PPO
Blue Cross Pathway
Blue Cross Pathway Enhanced
Cigna
Connecticare
Emblem Selectcare
HIP
Medicare
Oxford
United Healthcare
United Healthcare Compass

If your particular insurance plan is not listed, you may still have coverage subject to the availability of 'out-of-network' benefits. Please do not hesitate to contact our office if you have questions regarding your insurance coverage.

Education

SUNY Upstate Medical University, Syracuse

Internship

NewYork-Presbyterian - Weill Cornell Medical Center, New York

Residency

NewYork-Presbyterian - Weill Cornell Medical Center, New York

Fellowship

Hospital for Special Surgery, New York

Certification

American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Rheumatology

State Licensure

New York

Selected Publications

Fernandez D, Kirou KA. What Causes Lupus Flares? (2016) Current Rheumatology Reports. 18(3):14. doi: 1007/s11926-016-0562-3.

Fernandez DR, Markenson JA. Gout and Hyperuricemia – Serious Risk Factors for Morbidity and Mortality or Just Indicator "The Good Life" – The Evidence to Date. (2015) Current Treatment Options in Rheumatology. 1(2):167-181.

Caza TN, Fernandez DR, Talaber G, Oaks Z, Haas M, Madaio MP, Lai ZW, Miklossy G, Singh RR, Chudakov DM, Malomi W,Banki K, Perl A. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target fortreatment of SLE. (2014) Annals of the Rheumatic Diseases. 73(10):1888-97. (PMCID: PMC4047212)

Fernandez D, Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? (2010) DiscoveryMedicine. 9(46):173-8. (PMCID: PMC4047522)

Hanczko R, Fernandez DR, Doherty E, Qian Y Vas G, Niland B, Telarico T, Garba A, Banerjee S, Middleton FA, Barrett D,Barcza M, Banki K, Landas SK, Perl A. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. (2009) Journal of Clinical Investigation. 119(6):1546-57. (PMCID: PMC2689120)

Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, Phillips PE, Crow MK, Oess S, Muller-Esterl W, Perl A.Activation of mammalian target of rapamycin controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulatedlysosomal degradation. (2009) Journal of Immunogy. 182(4):2063-73. (PMCID: PMC2676112)

Perl A, Fernandez DR, Telarico T, Doherty E, Francis L, Phillips PE. T-cell and B-cell signaling biomarkers and treatmenttargets in lupus. (2009) Current Opinions in Rheumatology. 21(5):454-464.

Fernandez D, Bonilla E, Phillips P, Perl A. Signaling Abnormalities in Systemic Lupus Erythematosus as Potential DrugTargets. (2006) Endocrine, Metabolic & Immune Disorders – Drug Targets. 6(4):305-311.

Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. (2006) Arthritis & Rheumatism. 54(9):2983-8. (PMCID:PMC4034146)

For more publications, please see the PubMed listing.

Research Interests

Currently studying the role of cell-free mitochondrial DNA in triggering interferon production and disease flares in patients withsystemic lupus erythematosus, as well as the effect of medications used to treat lupus patients on mitochondrial DNA release.

Additionally, working to identify clinical features in a large cohort of lupus patients that may allow us to better define subgroups of patients.